190367-57-8

Basic information

• Product Name: Benzoic acid, 4-chloro-2-methyl-3-nitro-, methyl ester
• CAS NO: 190367-57-8
• Molecular Formula: C9H8ClNO4
• Molecular Weight: 229.62
• Mol File: 190367-57-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-chloro-2-methyl-3-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-chloro-2-methyl-3-nitro-, methyl ester(190367-57-8)
• EPA Substance Registry System: Benzoic acid, 4-chloro-2-methyl-3-nitro-, methyl ester(190367-57-8)

Safety Data

• Hazardous Substances Data: 190367-57-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 7499-07-2 4-chloro-2-methylbenzoic acid 
• 74-11-3 para-chlorobenzoic acid 
• 950915-10-3 4-chloro-2-methyl-3-nitro-benzoic acid 
• 476660-41-0 4-chloro-2-methyl-5-nitrobenzoic acid 

Downstream Products

• 390816-48-5 4-cyclohexylamino-2-methyl-5-nitrobenzoic acid methyl ester 
• 390816-49-6 4-cyclohexylamino-2-methyl-3-nitrobenzoic acid methyl ester 
• 190367-93-2 3-Methanesulfonyl-2-methyl-4-(pyridin-3-yloxy)-benzoic acid methyl ester 
• 190367-59-0 4-Chloro-3-methanesulfonyl-2-methyl-benzoic acid methyl ester 
• 1026710-65-5 4-Chloro-2-methyl-3-sulfino-benzoic acid methyl ester 
• 190367-58-9 methyl 3-amino-4-chloro-2-methylbenzoate 

Relevant articles and documents

Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis

The presence and growth of endometrial tissue outside the uterine cavity in endometriosis patients are primarily driven by hormone-dependent and inflammatory processes - the latter being frequently associated with severe, acute, and chronic pelvic pain. T

Viral polymerase inhibitors

An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein R1 is selected from: H, haloalkyl, (C1-6)alkyl, (C2-6)alkenyl, (C3-7)cycloalkyl, (C2-6)alkynyl, (C5-7)cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C6-10)bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR5, wherein R5 is H, halogen, haloalkyl, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; X is N or CR5; D is N or CR5; each of Y1 and Y2 is independently O or S; Z is O, N, or NRz wherein Rz is H, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; R3 and R4 are each independently H, (C1-6)alkyl, first (C3-7)cycloalkyl or 6- or 10-membered aryl, Het (C1-6)alkyl-6- or 10-membered aryl, (C1-6)alkyl-Het; or each R3 and R4 are independently covalently bonded together to form second (C3-7)cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R3 or R4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R7 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; or R7 is covalently bonded to either of R3 or R4 to form a heterocycle; A is (C1-6) alkyl-CONHR8 wherein R8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.